Micro-ultrasound is as effective as MRI in detecting prostate cancer

Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer

Transperineal biopsy improves prostate cancer detection

Adjuvant docetaxel shows no significant advantage compared to surveillance in high-risk prostate cancer after 10 years

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy

EAU 2025: Updates in NMIBC

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC

Belzutifan is more efficacious than everolimus in the treatment of metastatic renal cell carcinoma

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC